| Market Capitalization (Millions $) |
26,216 |
| Shares
Outstanding (Millions) |
207 |
| Employees |
2,844 |
| Revenues (TTM) (Millions $) |
5,361 |
| Net Income (TTM) (Millions $) |
1,432 |
| Cash Flow (TTM) (Millions $) |
1,520 |
| Capital Exp. (TTM) (Millions $) |
96 |
Business Description
Company Profile: Incyte Corporation
Overview:
Incyte Corporation is a leading biopharmaceutical company based in Wilmington, Delaware, United States. Founded in 1991, the company specializes in the discovery, development, and commercialization of innovative therapeutics targeting a range of serious diseases, including cancer and autoimmune disorders.
Divisions:
Incyte operates through two primary divisions:
1. Research and Development: Focused on small molecule drug discovery, immunology, inflammation, and oncology, this division is dedicated to advancing therapeutic options to improve patient outcomes.
2. Commercial: This division is responsible for the commercialization of approved therapies, ensuring that patients and healthcare providers have access to Incytes innovative treatments.
Key Products:
- Jakafi (Ruxolitinib): Incyte’s flagship product, Jakafi is the first and only FDA-approved treatment for polycythemia vera (PV) and myelofibrosis. It has demonstrated significant improvements in disease-related symptoms and overall survival in patients.
- Olumiant (Baricitinib): Developed in collaboration with Eli Lilly and Company, Olumiant is a JAK inhibitor approved for the treatment of rheumatoid arthritis, showcasing Incytes commitment to addressing autoimmune diseases.
- Epacadostat (INCMGA0012): This novel IDO1 inhibitor targets the immune systems response to cancer and is under development in partnership with Merck & Co.
Pipeline:
Incyte has a robust pipeline of therapeutics in various stages of development. The company invests heavily in research technologies and collaborates with academic institutions and industry partners, ensuring a consistent flow of innovative therapeutic targets.
Recognition and Awards:
Incyte Corporation has received numerous accolades for its contributions to the biopharmaceutical industry, including recognition as one of the 100 Best Companies to Work for in Americaby Fortune Magazine in 2020. The company was also honored with the 2018 Lasker-DeBakey Clinical Medical Research Award for its groundbreaking work on Jakafi.
Conclusion:
Incyte Corporation stands at the forefront of biopharmaceutical innovation, dedicated to developing and commercializing treatments for significant medical conditions. With a strong focus on research, development, and collaborative partnerships, Incyte is well-equipped to continue making impactful strides in improving patient care and driving advancements in the industry for years to come.
Company Address: 1801 Augustine Cut-Off Zagreb 19803 City of Zagreb
Company Phone Number: 498-6700 Stock Exchange / Ticker: NASDAQ INCY
|
1.26% 
86.78 %